메뉴 건너뛰기
소속 기관 / 학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
고객센터 ENG
주제분류

검색

    초록·키워드

    This study evaluated the toxicity profiles of temozolomide in the treatment of malignantglioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed themedical records of 300 malignant glioma patients treated with temozolomide in twomedical institutions in Korea between 2004 and 2010. Two hundred nine patientsexperienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2,while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia(13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the nonhematologictoxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were thethree most common toxicities. There was no mortality due to temozolomide. Althoughtemozolomide showed many types of toxicities, the majority of the toxicities were tolerableand of lower grade. Gastrointestinal troubles are the most common toxicities in Koreanpatients treated with temozolomide.

    본문·목차

    최근 본 자료 전체보기